866-997-4948(US-Canada Toll Free)

Global Market Study on Hemoglobinopathy: Europe Estimated to be the Dominant Regional Market in 2016

Published By :

Persistence Market Research

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 131 Pages

This report by Persistence Market Research examines the global hemoglobinopathy market for the period 20162024. The primary objective of the report is to offer updates and information related to market opportunities in the global hemoglobinopathy market. The global hemoglobinopathy market report begins with an exhaustive executive summary giving the report data overview and the market taxonomy or segments covered in the report. It is followed by an overview of market dynamics of the global hemoglobinopathy market, which includes an in-depth analysis of key trends, drivers, restraints, and opportunities, and reimbursement scenario influencing the growth of the global hemoglobinopathy market. Impact analysis of key growth drivers and restraints based on a weighted average model have been included in the report after detailed analysis of individual regions to better equip readers with meaningful insights on ongoing developments in the global hemoglobinopathy market.

Based on indication type, the market has been segmented into Sickle Cell Disease, Beta Thalassemia, and Alpha Thalassemia. A detailed analysis has been provided for these segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and BPS analysis. Based on test type, the market has been segmented into red blood cell (RBC) count test, genetic testing, hemoglobin by high performance liquid chromatography (HPLC) test, hemoglobin isoelectric (Hb IEF) focusing, hemoglobin electrophoresis (Hb ELP) test, and hemoglobin solubility test. The next section of the report analyzes the global hemoglobinopathy market by region and provides a comprehensive market outlook for 20162024. The report also analyzes the impact of drivers and restraints in each region. Key regions assessed in this report include North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA). These sections evaluate the present scenario and future growth prospects of the global hemoglobinopathy market during the period 20162024. We have considered 2015 as the base year and provided data for the forecast period, i.e., 20162024.

In the final section of the report on the global hemoglobinopathy market, a competitive landscape is included to provide report audiences with a dashboard view based on categories of providers in the global hemoglobinopathy market product portfolio and key differentiators. Key categories of providers covered in the report are hemoglobinopathy diagnosis devices, ready-to-use kits, and reagents manufacturers. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the global hemoglobinopathy market value chain. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on an in-depth assessment of their capabilities and successes in the global hemoglobinopathy market. Detailed profiles of providers are also included in the scope of the report to evaluate their long- and short-term strategies, key offerings, SWOT analysis, and recent developments in the global hemoglobinopathy market. Key competitors covered in terms of manufacturers include Abbott Diagnostics, Bio-Rad Laboratories Inc., Danaher Corporation, Mindray Medical International Ltd., Nexcelom Bioscience LLC., Nihon Kohden Corporation, PerkinElmer Inc., Siemens Healthineers, and Sysmex Corporation.

Research methodology

To ascertain the global hemoglobinopathy market size, we have considered revenue generated by device manufacturers. The forecast presented here assesses the total revenue by value across the global hemoglobinopathy market. In order to offer an accurate forecast, we started by sizing up the current market, which forms the basis of how the global hemoglobinopathy market is expected to develop in the future. Given the characteristics of the market, we have triangulated the outcome of three different types of analyses based on supply side, downstream industry demand, and the economic envelope. In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyze it based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market and to identify the right opportunities across the global hemoglobinopathy market.

The different segments of the global hemoglobinopathy market are analyzed in terms of Basis Point Share (BPS) to understand individual segments relative contribution to market growth. This detailed level of information is important for identifying various key trends in the global hemoglobinopathy market. Another important feature of this report is the analysis of key segments in terms of absolute dollar opportunity, critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective in the global hemoglobinopathy market. To understand key growth segments in terms of growth and adoption for hemoglobinopathy diagnosis globally, Persistence Market Research has developed the global hemoglobinopathy market attractiveness index to help providers identify real market opportunities.

Company Profiles 

  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • Mindray Medical International Ltd
  • Nexcelom Bioscience LLC.
  • Nihon Kohden Europe Ltd
  • PerkinElmer Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH
  • Others

Table of Content

1. Executive Summary

2. Market Taxonomy

3. Global Hemoglobinopathy Market Analysis Scenario

3.1. Pricing Analysis
3.1.1. Pricing Assumptions
3.1.2. Price Analysis per Region
3.2. Market Size (US$ Mn) and Forecast
3.2.1. Market Size and Y-o-Y Growth
3.2.2. Absolute $ Opportunity
3.3. Market Overview
3.3.1. Global Hemoglobinopathy Market Reimbursement Scenario

4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Key Trends
4.6. Forecast Factors Relevance and Impact

5. Global Hemoglobinopathy Market Analysis and Forecasts, by Indication
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis by Indication
5.3. Y-o-Y Growth Projections by Indication
5.4. Market Value Forecast, 20162024
5.4.1. Sickle Cell Disease
5.4.2. Beta Thalassemia
5.4.3. Alpha Thalassemia
5.5. Market Attractiveness by Indication

6. Global Hemoglobinopathy Market Analysis and Forecasts, by End User
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis by End User
6.3. Y-o-Y Growth Projections by End User
6.4. Market Value Forecast by End User, 20162024
6.4.1. Hospitals
6.4.2. Diagnostics Laboratories
6.4.3. Clinics
6.5. Market Attractiveness by End User

7. Global Hemoglobinopathy Market Analysis and Forecasts, by Test Type
7.1. Introduction
7.2. Basis Point Share (BPS) Analysis by Test Type
7.3. Y-o-Y Growth Projections by Test Type
7.4. Market Value Forecast by Test Type, 20162024
7.4.1. Routine Red Blood Cell (RBC) Count
7.4.2. Genetic Testing
7.4.3. Hemoglobin by High Performance Liquid Chromatography
7.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
7.4.5. Hemoglobin electrophoresis (Hb ELP)
7.4.6. Hemoglobin Solubility Test
7.5. Market Attractiveness by Test Type

8. Global Hemoglobinopathy Market Analysis and Forecasts, by Region
8.1. Basis Point Share (BPS) Analysis by Country
8.2. Y-o-Y Growth Projections by Country
8.3. Market Value Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. APAC
8.3.5. MEA
8.4. Market Attractiveness by Country

9. North America Hemoglobinopathy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Key Findings
9.2. Market Value Forecast by Indication, 20162024
9.2.1. Sickle Cell Disease
9.2.2. Beta Thalassemia
9.2.3. Alpha Thalassemia
9.3. Market Value Forecast by End User, 20162024
9.3.1. Hospitals
9.3.2. Diagnostics Labs
9.3.3. Clinics
9.4. Market Value Forecast by Test Type, 20162024
9.4.1. Routine Red Blood Cell (RBC) Count
9.4.2. Genetic Testing
9.4.3. Hemoglobin by High Performance Liquid Chromatography
9.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
9.4.5. Hemoglobin electrophoresis (Hb ELP)
9.4.6. Hemoglobin Solubility Test
9.5. Market Value Forecast by Country, 20162024
9.5.1. US
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. by Indication
9.6.2. by End User
9.6.3. by Test Type
9.7. Drivers and Restraints: Impact Analysis

10. Latin America Hemoglobinopathy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Key Findings
10.2. Market Value Forecast by Indication, 20162024
10.2.1. Sickle Cell Disease
10.2.2. Beta Thalassemia
10.2.3. Alpha Thalassemia
10.3. Market Value Forecast by End User, 20162024
10.3.1. Hospitals
10.3.2. Diagnostics Labs
10.3.3. Clinics
10.4. Market Value Forecast by Test Type, 20162024
10.4.1. Routine Red Blood Cell (RBC) Count
10.4.2. Genetic Testing
10.4.3. Hemoglobin by High Performance Liquid Chromatography
10.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
10.4.5. Hemoglobin electrophoresis (Hb ELP)
10.4.6. Hemoglobin Solubility Test
10.5. Market Value Forecast by Country, 20162024
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Mexico
10.5.4. Rest of Latin America
10.6. Market Attractiveness Analysis
10.6.1. by Indication
10.6.2. by End User
10.6.3. by Test Type
10.7. Drivers and Restraints: Impact Analysis

11. Europe Hemoglobinopathy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Key Findings
11.2. Market Value Forecast by Indication, 20162024
11.2.1. Sickle Cell Disease
11.2.2. Beta Thalassemia
11.2.3. Alpha Thalassemia
11.3. Market Value Forecast by End User, 20162024
11.3.1. Hospitals
11.3.2. Diagnostics Labs
11.3.3. Clinics
11.4. Market Value Forecast by Test Type, 20162024
11.4.1. Routine Red Blood Cell (RBC) Count
11.4.2. Genetic Testing
11.4.3. Hemoglobin by High Performance Liquid Chromatography
11.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
11.4.5. Hemoglobin electrophoresis (Hb ELP)
11.4.6. Hemoglobin Solubility Test
11.5. Market Value Forecast by Country, 20162024
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Poland
11.5.7. Russia
11.5.8. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. by Indication
11.6.2. by End User
11.6.3. by Test Type
11.7. Drivers and Restraints: Impact Analysis

12. APAC Hemoglobinopathy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Key Findings
12.2. Market Value Forecast by Indication, 20162024
12.2.1. Sickle Cell Disease
12.2.2. Beta Thalassemia
12.2.3. Alpha Thalassemia
12.3. Market Value Forecast by End User, 20162024
12.3.1. Hospitals
12.3.2. Diagnostics Labs
12.3.3. Clinics
12.4. Market Value Forecast by Test Type, 20162024
12.4.1. Routine Red Blood Cell (RBC) Count
12.4.2. Genetic Testing
12.4.3. Hemoglobin by High Performance Liquid Chromatography
12.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
12.4.5. Hemoglobin electrophoresis (Hb ELP)
12.4.6. Hemoglobin Solubility Test
12.5. Market Value Forecast by Country, 20162024
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia
12.5.5. Rest of APAC
12.6. Market Attractiveness Analysis
12.6.1. by Indication
12.6.2. by End User
12.6.3. by Test Type
12.7. Drivers and Restraints: Impact Analysis

13. MEA Hemoglobinopathy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Key Findings
13.2. Market Value Forecast by Indication, 20162024
13.2.1. Sickle Cell Disease
13.2.2. Beta Thalassemia
13.2.3. Alpha Thalassemia
13.3. Market Value Forecast by End User, 20162024
13.3.1. Hospitals
13.3.2. Diagnostics Labs
13.3.3. Clinics
13.4. Market Value Forecast by Test Type, 20162024
13.4.1. Routine Red Blood Cell (RBC) Count
13.4.2. Genetic Testing
13.4.3. Hemoglobin by High Performance Liquid Chromatography
13.4.4. Hemoglobin Isoelectric Focusing (Hb IEF)
13.4.5. Hemoglobin electrophoresis (Hb ELP)
13.4.6. Hemoglobin Solubility Test
13.5. Market Value Forecast by Country, 20162024
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
13.6. Market Attractiveness Analysis
13.6.1. by Indication
13.6.2. by End User
13.6.3. by Test Type
13.7. Drivers and Restraints: Impact Analysis

14. Competition Landscape
14.1. Competition Dashboard
14.2. Company Profiles (Details Overview, Financials, Strategy, Recent Developments)
14.2.1. Abbott Diagnostics
14.2.2. Bio-Rad Laboratories, Inc.
14.2.3. Danaher Corp.
14.2.4. Mindray Medical International Ltd
14.2.5. Nexcelom Bioscience LLC.
14.2.6. Nihon Kohden Europe Ltd
14.2.7. PerkinElmer Inc.
14.2.8. Siemens Healthineers
14.2.9. Sysmex Europe GmbH

15. Assumptions and Acronyms Used

16. Research Methodology

List of Table

Table 01: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 20152024
Table 02: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 20152024
Table 03: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 20152024
Table 04: Global Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Region, 20152024
Table 05: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 20152024
Table 06: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 20152024
Table 07: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 20152024
Table 08: North America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 20152024
Table 09: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 20152024
Table 10: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 20152024
Table 11: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 20152024
Table 12: Latin America Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 20152024
Table 13: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 20152024
Table 14: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 20152024
Table 15: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 20152024
Table 16: Europe Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 20152024
Table 17: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 20152024
Table 18: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 20152024
Table 19: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 20152024
Table 20: Asia Pacific Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 20152024
Table 21: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Country, 20152024
Table 22: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By End User, 20152024
Table 23: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Indication, 20152024
Table 24: Middle East & Africa Hemoglobinopathy Market Value (US$ Mn) Analysis and Forecast By Test Type, 20152024

List of Chart

Figure 01: Routine Red Blood Cell (RBC) Count Test Pricing Difference (US$) By Region, 2015 A
Figure 02: Genetic Testing Pricing Difference (US$) By Region, 2015 A
Figure 03: Hemoglobin by high performance liquid chromatography (HPLC) Test Pricing Difference (US$) By Region, 2015 A
Figure 04: Hemoglobin isoelectric focusing (Hb IEF) Pricing Difference (US$) By Region, 2015 A
Figure 05: Hemoglobin electrophoresis (Hb ELP) Test Pricing Difference (US$) By Region, 2015 A
Figure 06: Hemoglobin solubility test (SST) Pricing Difference (US$) By Region, 2015 A
Figure 07: Global Hemoglobinopathy Market Value (US$ Mn) Forecast, 20162024
Figure 08 : Global Hemoglobinopathy Market Absolute $ Opportunity (US$ Mn), 20162024
Figure 09: Global Hemoglobinopathy Market Share and BPS Analysis (%) By Indication, 2016 & 2024
Figure 10: Global Hemoglobinopathy Y-o-Y growth (%) By Indication, 20162024
Figure 11: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Sickle Cell Disease Segment, 20152024
Figure 12: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Beta Thalassemia Segment, 20152024
Figure 13: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Alpha Thalassemia Segment, 20152024
Figure 14: Global Hemoglobinopathy Market Attractiveness Analysis By Indication, 20162024
Figure 15: Global Hemoglobinopathy Market Share and BPS Analysis (%) By End User, 2016 & 2024
Figure 16: Global Hemoglobinopathy Y-o-Y growth (%) By End User, 20162024
Figure 17: Global Hemoglobinopathy Market Absolute $ Opportunity By Hospitals Segment, 20162024
Figure 18: Global Hemoglobinopathy Market Absolute $ Opportunity By Diagnostics Laboratories Segment, 20162024
Figure 19: Global Hemoglobinopathy Market Absolute $ Opportunity By Clinics Segment, 20162024
Figure 20: Global Hemoglobinopathy Market Attractiveness Analysis By End-user, 20162024
Figure 21: Hemoglobinopathy Market Share Analysis (%) By Test Type, 2016 & 2024
Figure 22: Global Hemoglobinopathy Y-o-Y growth (%) By Test Type, 20162024
Figure 23: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By RBC Count, 20152024
Figure 24: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Genetic Testing, 20152024
Figure 25: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin HPLC, 20152024
Figure 26: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Isoelectric Focusing, 20152024
Figure 27: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Electrophoresis, 20152024
Figure 28: Global Hemoglobinopathy Absolute $ Opportunity (US$ Mn) By Hemoglobin Solubility Test, 20152024
Figure 29: Global Hemoglobinopathy Market Attractiveness Analysis By End User, 20162024
Figure 30: Global Hemoglobinopathy Market Value (US$ Mn) and CAGR (%) By Region, 2015, 2020, and 2024
Figure 31: Global Hemoglobinopathy Market Share Analysis (%) By Region, 2016 & 2024
Figure 32: Global Hemoglobinopathy Y-o-Y growth (%) By Region, 20162024
Figure 33: North America Hemoglobinopathy Market Absolute $ Opportunity, 20162024
Figure 34: Latin America Hemoglobinopathy Market Absolute $ Opportunity, 20162024
Figure 35: Europe Hemoglobinopathy Market Absolute $ Opportunity, 20162024
Figure 36: APAC Hemoglobinopathy Market Absolute $ Opportunity, 20162024
Figure 37: MEA Hemoglobinopathy Market Absolute $ Opportunity, 20162024
Figure 38: Global Hemoglobinopathy Market Attractiveness Analysis By Region, 20162024
Figure 39: North America Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 40: North America Hemoglobinopathy Y-o-Y growth (%) By Country, 20162024
Figure 41: North America Hemoglobinopathy Market Attractiveness Analysis By Indication, 20162024
Figure 42: North America Hemoglobinopathy Market Attractiveness Analysis By End User, 20162024
Figure 43: North America Hemoglobinopathy Market Attractiveness Analysis By Test Type, 20162024
Figure 44: Latin America Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 45: Latin America Hemoglobinopathy Y-o-Y growth (%) By Country, 20162024
Figure 46: Latin America Hemoglobinopathy Market Attractiveness Analysis By Indication, 20162024
Figure 47: Latin America Hemoglobinopathy Market Attractiveness Analysis By End User, 20162024
Figure 48: Latin America Hemoglobinopathy Market Attractiveness Analysis By Test Type, 20162024
Figure 49: Europe Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 50: Europe Hemoglobinopathy Y-o-Y growth (%) By Country, 20162024
Figure 51: Europe Hemoglobinopathy Market Attractiveness Analysis By Indication, 20162024
Figure 52: Europe Hemoglobinopathy Market Attractiveness Analysis By End User, 20162024
Figure 53: Europe Hemoglobinopathy Market Attractiveness Analysis By Test Type, 20162024
Figure 54: Asia Pacific Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 55: Asia Pacific Hemoglobinopathy Y-o-Y growth (%) By Country, 20162024
Figure 56: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By Indication, 20162024
Figure 57: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By End User, 20162024
Figure 58: Asia Pacific Hemoglobinopathy Market Attractiveness Analysis By Test Type, 20162024
Figure 59: Middle East & Africa Hemoglobinopathy Market Share Analysis (%) By Country, 2016 & 2024
Figure 60: Middle East & Africa Hemoglobinopathy Y-o-Y growth (%) By Country, 20162024
Figure 61: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By Indication, 20162024
Figure 62: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By End User, 20162024
Figure 63: Middle East & Africa Hemoglobinopathy Market Attractiveness Analysis By Test Type, 20162024

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *